Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
1.
BMC Nephrol ; 19(1): 238, 2018 09 19.
Article de Anglais | MEDLINE | ID: mdl-30231858

RÉSUMÉ

BACKGROUND: Liver cirrhosis is characterized by avid sodium retention where the activation of the renin angiotensin aldosterone system (RAAS) is considered to be the hallmark of the sodium retaining mechanisms. The direct effect of angiotensin II (ANGII) on the AT-1 receptor in the proximal tubules is partly responsible for the sodium retention. The aim was to estimate the natriuretic and neurohumoral effects of an ANGII receptor antagonist (losartan) in the late phase of the disease in a rat model of liver cirrhosis. METHODS: Bile duct ligated (BDL) and sham operated rats received 2 weeks of treatment with losartan 4 mg/kg/day or placebo, given by gastric gavage 5 weeks after surgery. Daily sodium and potassium intakes and renal excretions were measured. RESULTS: The renal sodium excretion decreased in the BDL animals and this was not affected by losartan treatment. At baseline the plasma renin concentration (PRC) was similar in sham and BDL animals, but increased urinary excretion of ANGII and an increase P-Aldosterone was observed in the placebo treated BDL animals. The PRC was more than 150 times higher in the losartan treated BDL animals (p < 0.001) which indicated hemodynamic impairment. CONCLUSIONS: Losartan 4 mg/kg/day did not increase renal sodium excretion in this model of liver cirrhosis, although the urinary ANGII excretion was increased. The BDL animals tolerated Losartan poorly, and the treatment induced a 150 times higher PRC.


Sujet(s)
Antagonistes du récepteur de type 1 de l'angiotensine-II/pharmacologie , Modèles animaux de maladie humaine , Cirrhose du foie/urine , Losartan/pharmacologie , Système rénine-angiotensine/physiologie , Sodium/urine , Antagonistes du récepteur de type 1 de l'angiotensine-II/usage thérapeutique , Animaux , Cholestase/sang , Cholestase/traitement médicamenteux , Cholestase/urine , Rein/effets des médicaments et des substances chimiques , Rein/métabolisme , Cirrhose du foie/sang , Cirrhose du foie/traitement médicamenteux , Losartan/usage thérapeutique , Mâle , Rats , Rat Wistar , Système rénine-angiotensine/effets des médicaments et des substances chimiques , Sodium/sang
2.
Eur J Clin Microbiol Infect Dis ; 34(10): 2017-21, 2015 Oct.
Article de Anglais | MEDLINE | ID: mdl-26205664

RÉSUMÉ

In Europe, infections with Puumala hantavirus cause nephropathia epidemica. Presently the risk factors predicting severe kidney damage after Puumala virus infection are not well known. The objective of the study was to investigate environmental and individual factors predicting severe kidney damage caused by serologically established Puumala infections. In a nationwide cohort study we investigated all serologically established Puumala infections in Southern Denmark from 1996 to 2012. A total of 184 patients had serologically verified Puumala virus infection. In patients with Puumala virus infections the decrease of platelet counts preceded acute kidney failure. Multivariable logistic regression demonstrated that recent activities in the forest, platelet counts, and flu-like symptoms predicted estimated glomerular filtration rates less than 30 mL/min/1.73 m(²), but not age, gender, fever, nor abdominal pain. Severe kidney damage in Puumala infections in Southern Denmark is associated with the risk of recent activities in the forest.


Sujet(s)
Atteinte rénale aigüe/sang , Atteinte rénale aigüe/étiologie , Fièvre hémorragique avec syndrome rénal/sang , Fièvre hémorragique avec syndrome rénal/complications , Adulte , Études de cohortes , Danemark , Femelle , Humains , Mâle , Adulte d'âge moyen , Numération des plaquettes , Valeur prédictive des tests , Virus Puumala , Facteurs de risque
3.
Acta Physiol Scand ; 184(2): 161-9, 2005 Jun.
Article de Anglais | MEDLINE | ID: mdl-15916676

RÉSUMÉ

AIM: In mineralocorticoid target cells 11-beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) converts glucocorticoids into non-active metabolites thereby protecting the mineralocorticoid receptor (MR) from stimulation by glucocorticoids. In nephrotic syndrome, a decreased activity of 11betaHSD2 has been suggested to allow glucocorticoids to stimulate MR, thereby contributing to sodium retention. We tested this hypothesis in the puromycin aminonucleoside model of nephrotic syndrome in rats. METHODS: Complete sodium and potassium intakes and excretions (faeces and urine) were measured in rats in metabolic cages. RNase protection assay of mRNA and Western blotting of protein were used to estimate renocortical expression of 11betaHSD2 and of the MR downstream effector serum and glucocorticoid induced kinase (SGK). In an intervention series, dexamethasone was given [10 microg (100 g bw)(-1)] to suppress endogenous glucocorticoids in the proteinuric stage during active sodium retention. RESULTS: Nephrotic rats developed proteinuria, positive sodium balance, decreased plasma aldosterone concentration, and decreased urinary Na(+)/K(+) ratio. 11betaHSD2 mRNA expression was down-regulated but protein expression was unchanged. SGK mRNA and phosphorylated SGK protein were up-regulated while total SGK protein expression was unchanged. Dexamethasone treatment, which suppressed plasma corticosterone concentration, did not correct sodium balance or fluid retention in nephrotic rats. CONCLUSION: Our results do not support the hypothesis that stimulation of the MR by endogenous glucocorticoids induces sodium and fluid retention in experimental nephrotic syndrome in rats.


Sujet(s)
11-beta-Hydroxysteroid dehydrogenase type 2/métabolisme , Syndrome néphrotique/métabolisme , Sodium/métabolisme , 11-beta-Hydroxysteroid dehydrogenase type 2/analyse , Aldostérone/sang , Animaux , Corticostérone/sang , Dexaméthasone/pharmacologie , Modèles animaux de maladie humaine , Régulation négative/physiologie , Fèces/composition chimique , Glucocorticoïdes/pharmacologie , Cortex rénal/effets des médicaments et des substances chimiques , Cortex rénal/métabolisme , Mâle , Syndrome néphrotique/enzymologie , Phosphorylation , Potassium/métabolisme , Potassium/urine , Protéinurie/enzymologie , Protéinurie/métabolisme , Puromycine aminonucléoside , ARN messager , Rats , Rat Sprague-Dawley , Sodium/urine , Régulation positive/physiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE